
ORYZF
Healthcare · Biotechnology · $253.9M market cap
$3.100.00 (0.0%)Nov 13, 9:30 AM EST
Latest report
Before the open
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Dec 31, 2026
EPS trend, 90 days to now · 0.0% over 90 days · 30-day revisions 0 up, 0 down
Beat estimates in 0 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Oct 22, 2025 | Before the open | — | 0.01 | — |
| May 5, 2025 | Before the open | — | -0.03 | — |
| Feb 24, 2025 | Before the open | — | -0.02 | — |
| Jul 31, 2024 | Before the open | — | 0.00 | — |
| May 6, 2024 | After the close | — | -0.02 | — |
| Feb 28, 2024 | Before the open | — | -0.03 | — |
| Feb 17, 2023 | Before the open | -0.05 | -0.04 | +20.0% |
| Nov 1, 2022 | After the close | -0.05 | -0.01 | +80.0% |
| Jul 22, 2022 | Before the open | -0.03 | 0.01 | +133.3% |
| May 5, 2022 | Before the open | -0.04 | -0.03 | +25.0% |
| Feb 7, 2022 | Before the open | -0.04 | -0.04 | 0.0% |
| Oct 28, 2021 | Before the open | -0.03 | -0.02 | +33.3% |
| Jul 29, 2021 | Before the open | -0.03 | 0.02 | +166.7% |
Oryzon Genomics S.A., a clinical stage biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS (central nervous system), oncology, and hematology disorders. Its clinical phase compounds include iadademstat (ORY-1001), a selective LSD1 inhibitor that is in Phase II trials for oncology; and vafidemstat (ORY-2001), a CNS-optimized LSD1…
| May 7, 2021 |
| Before the open |
| -0.02 |
| -0.04 |
| -100.0% |
| Feb 22, 2021 | Before the open | -0.06 | -0.02 | +66.7% |
| Oct 25, 2020 | After the close | -0.07 | -0.02 | +71.4% |
| Jul 22, 2020 | Before the open | -0.11 | 0.00 | +100.0% |
| May 11, 2020 | Before the open | -0.06 | -0.03 | +50.0% |
| Feb 23, 2020 | After the close | -0.07 | -0.01 | +85.7% |
| Oct 25, 2019 | Before the open | -0.06 | -0.02 | +66.7% |
| Jul 30, 2019 | Before the open | -0.06 | -0.05 | +16.7% |
| May 13, 2019 | Before the open | -0.05 | -0.02 | +67.8% |
| Feb 15, 2019 | Before the open | -0.03 | -0.02 | +33.3% |
| Nov 2, 2018 | Time not confirmed | -0.04 | -0.03 | +25.0% |
| Jul 30, 2018 | Before the open | -0.05 | 0.05 | +200.0% |
| May 9, 2018 | Before the open | -0.05 | -0.03 | +40.0% |
| Feb 19, 2018 | Before the open | — | -0.04 | — |